Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.23.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
OPERATING ACTIVITIES    
Net income (loss) $ 800 $ (89)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Provision for doubtful accounts (122) (84)
Depreciation 8,621 8,131
Loss on disposal of and reserve adjustments for medical equipment 1,278 1,450
Gain on sale of medical equipment (1,990) (1,348)
Amortization of intangible assets 743 2,125
Amortization of deferred debt issuance costs 99 55
Stock-based compensation 2,799 3,236
Deferred income taxes 325 (331)
Changes in assets - (increase)/decrease:    
Accounts receivable (1,035) (607)
Inventories (1,270) (922)
Other current assets (1,090) 224
Other assets (2,304) (89)
Changes in liabilities - (decrease)/increase:    
Accounts payable and other liabilities (289) 1,200
NET CASH PROVIDED BY OPERATING ACTIVITIES 6,565 12,951
INVESTING ACTIVITIES    
Purchase of medical equipment (8,503) (10,452)
Purchase of property and equipment (616) (571)
Proceeds from sale of medical equipment, property and equipment 3,429 2,597
NET CASH USED IN INVESTING ACTIVITIES (5,690) (8,426)
FINANCING ACTIVITIES    
Principal payments on long-term debt (43,160) (31,089)
Cash proceeds from long-term debt 42,788 32,398
Debt issuance costs (229) 0
Cash payment of contingent consideration 0 (750)
Common stock repurchased as part of share repurchase program (153) (5,359)
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans (1,157) (698)
Cash proceeds from stock plans 1,032 1,150
NET CASH USED IN FINANCING ACTIVITIES (879) (4,348)
Net change in cash and cash equivalents (4) 177
Cash and cash equivalents, beginning of period 165 186
Cash and cash equivalents, end of period $ 161 $ 363